Suitability Petition From Hyman Phelps McNamara P.C.

Summary

A suitability petition has been filed with the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) by the law firm Hyman, Phelps & McNamara, P.C. The petition is available in two versions: a confidential business information attachment and a redacted version for public review on regulations.gov. The FDA will review the petition to determine whether it meets suitability requirements for the requested regulatory pathway.

About this source

Every FDA document on regulations.gov, the federal rulemaking portal. This is where the agency posts variances, advisory committee meeting notices, draft guidance for comment, citizen petition responses, and procedural rules that do not get a separate Federal Register slot. Around 240 a month. FDA's heavy regulations.gov use means tracking only the Federal Register misses a meaningful chunk of what the agency does day-to-day. Watch this if you manufacture devices, submit IND or NDA applications, run a lab, or advise sponsors on FDA process. GovPing publishes each posting with the docket, document type, division (CDER, CDRH, CFSAN), and comment window where one applies.

What changed

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Mentioned entities

Parties

Related changes

Omsav Pharma Flecainide Acetate ANDA 218093 Approved

Routine Apr 24, 2026 • FDA Drugs@FDA - New Applications and Actions • Healthcare & Life Sciences

Tigecycline ANDA 217477 Tentative Approval Hainan Poly Pharm

Routine Apr 24, 2026 • FDA Drugs@FDA - New Applications and Actions • Healthcare & Life Sciences

Micro Labs Escitalopram Oxalate, 5/10/20mg, Approved 22nd Apr

Routine Apr 24, 2026 • FDA Drugs@FDA - New Applications and Actions • Healthcare & Life Sciences